Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumor, Adult

In brief

This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.

Key facts

Study ID

NCT03905148

Run by

BeiGene

People needed

91

Starts

2019-05-01

Expected to finish

2025-10-23

Last updated by the study team

2026-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California Los Angeles — Santa Monica, California, United States
• MD Anderson — Houston, Texas, United States
• Blacktown Cancer and Haematology Centre — Blacktown, New South Wales, Australia
• The Prince of Wales Private Hospital - Specialist Medical Randwick — Randwick, New South Wales, Australia
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
• Linear Clinical Research — Nedlands, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.